Journal
JOURNAL OF NEURO-ONCOLOGY
Volume 123, Issue 3, Pages 433-440Publisher
SPRINGER
DOI: 10.1007/s11060-014-1676-y
Keywords
Glioblastoma; EGFRvIII; Immunotherapy; Glioma; Rindopepimut; Peptide vaccine
Categories
Ask authors/readers for more resources
Glioblastoma multiforme (GBM) is an extremely malignant brain tumor for which current therapies do little to remedy. Despite aggressive treatment with surgery, radiation therapy, and chemotherapy, tumors inevitably recur as a direct consequence of the infiltrative nature of GBM. The poor prognosis of patients with GBM underscores the clear and urgent need for more precise and potent therapies. Immunotherapy is emerging as a promising means to treat GBM based on the immune system's capacity to mediate tumor-specific cytotoxicity. In this review, we will discuss the use of peptide vaccines for the treatment of GBM. The simplicity of peptide vaccines and their ability to elicit tumor antigen-specific immune responses make them an invaluable tool for the study of brain tumor immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available